threo-4,6-dimethyl-5-nonanone | 41597-19-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: threo-4,6-dimethyl-5-nonanone
• 英文别名: 4,6-Dimethyl-nonanon-(5)；methyl-n-butyl ketone；4,6-dimethyl-nonan-5-one；4,6-Dimethyl-nonan-5-on；methylbutyl ketone；InChI=1/C11H22O/c1-5-7-9(3)11(12)10(4)8-6-2/h9-10H,5-8H2,1-4H；4,6-dimethylnonan-5-one
• CAS: 41597-19-7
• 化学式: C₁₁H₂₂O
• 分子量: 170.295
• InChiKey: YGDJOFDNZUXEMG-UHFFFAOYSA-N

物化性质

• 沸点：
  86 °C(Press: 13 Torr)
• 密度：
  0.818±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  12
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  2,4-dipropyl-penta-1,4-dien-3-one 在 甲醇 、 platinum(IV) oxide 作用下， 生成 threo-4,6-dimethyl-5-nonanone
  参考文献：
  名称：

  Mannich; Schumann, Chemische Berichte, 1936, vol. 69, p. 2306,2308

  摘要：

  DOI：

文献信息

• 5-Lipoxygenase-Activating Protein Inhibitor
  申请人：SCHAAB Kevin Murray

  公开号：US20090291981A1

  公开（公告）日：2009-11-26

  Described herein is the FLAP inhibitor 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxy-pyridin-3-yl)-benzyl]-5-(5-methyl-pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid, or a pharmaceutically acceptable salt thereof. Also described are methods of preparing the FLAP inhibitor, or a pharmaceutically acceptable salt thereof, including solvates, and polymorphs thereof. Also described herein are pharmaceutical compositions suitable for administration to a mammal that include the FLAP inhibitor, or a pharmaceutically acceptable salt thereof, and methods of using such pharmaceutical compositions for treating respiratory conditions or diseases, as well as other leukotriene-dependent or leukotriene mediated conditions or diseases.

  描述了一种FLAP抑制剂：3-[3-叔丁基硫基-1-[4-(6-乙氧基-吡啶-3-基)-苄基]-5-(5-甲基-吡啶-2-基甲氧基)-1H-吲哚-2-基]-2,2-二甲基丙酸，或其药用可接受盐。还描述了制备该FLAP抑制剂的方法，或其药用可接受盐，包括水合物和其多晶型。还描述了适合给予哺乳动物的药物组合物，包括FLAP抑制剂，或其药用可接受盐，以及使用此类药物组合物治疗呼吸系统疾病或疾病的方法，以及治疗其他白三烯依赖性或白三烯介导的条件或疾病的方法。
• [EN] A PROCESS FOR MANUFACTURING ZERANOL<br/>[FR] PROCÉDÉ DE FABRICATION DE ZÉRANOL
  申请人：INTERVET INT BV

  公开号：WO2010115478A1

  公开（公告）日：2010-10-14

  This invention is directed generally to a process for producing Zeranol that eliminates high pressure and high temperature hydrogenations and provides high selectivity for Zeranol at improved yields.

  这项发明通常涉及一种生产Zeranol的过程，该过程消除了高压和高温氢化反应，并且在高产率下为Zeranol提供了高选择性。
• METHOD FOR PREPARATION OF ARYL POLY(OXALKYL) QUATERNARY AMMONIUM COMPOUND
  申请人：Cheng Che Jim

  公开号：US20140187819A1

  公开（公告）日：2014-07-03

  A method for preparation of an aryl poly(oxalkyl) quaternary ammonium compound is provided, said method comprising steps of: 1) reacting a phenol with a dihalopolyalkylene ether under the action of a phase transfer catalyst, to obtain an arylpoly(oxalkyl) halide; 2) reacting said arylpoly(oxalkyl) halide with an amination reagent under the action of a phase transfer catalyst, to obtain an arylpoly(oxalkyl) amine; 3) reacting said arylpoly(oxalkyl) amine with an alkylation reagent, to obtain an aryl poly(oxalkyl) quaternary ammonium compound; wherein R 1 is H or a C 1 to C 16 alkyl group, located in the ortho, meta or para position; n is an integer of 2 to 6; R 2 is H or a C 1 to C 16 alkyl group; R 3 is H or a C 1 to C 16 alkyl group; R 4 is a C 1 to C 16 alkyl group; X 1 is Br or Cl; X is Cl, Br, or I. The preparation method according to the present invention requires low temperature and low pressure, the reaction time is short, and an overall yield can reach 75%. The operation is simple, the cost is low, and the product can be separated easily and have a purity of pharmaceutical grade, thereby facilitating the large-scale production.

  提供一种制备芳基聚（氧烷基）季铵化合物的方法，该方法包括以下步骤：1）在相转移催化剂的作用下，将酚与二卤代聚烯醚反应，得到芳基聚（氧烷基）卤化物；2）在相转移催化剂的作用下，将所述芳基聚（氧烷基）卤化物与胺化试剂反应，得到芳基聚（氧烷基）胺；3）将所述芳基聚（氧烷基）胺与烷基化试剂反应，得到芳基聚（氧烷基）季铵化合物；其中R1为H或C1至C16烷基，位于邻位、间位或对位；n为2至6的整数；R2为H或C1至C16烷基；R3为H或C1至C16烷基；R4为C1至C16烷基；X1为Br或Cl；X为Cl、Br或I。根据本发明的制备方法需要低温低压，反应时间短，总产率可达75%。操作简单，成本低，产品易于分离，具有药品级纯度，有利于大规模生产。
• <i>C</i>-Methylation of Alcohols, Ketones, and Indoles with Methanol Using Heterogeneous Platinum Catalysts
  作者：S. M. A. Hakim Siddiki、Abeda S. Touchy、Md. A. R. Jamil、Takashi Toyao、Ken-ichi Shimizu

  DOI：10.1021/acscatal.7b04442

  日期：2018.4.6

  heterogeneous catalytic method for the methylation of C–H bonds in alcohols, ketones, and indoles with methanol under oxidant-free conditions using a Pt-loaded carbon (Pt/C) catalyst in the presence of NaOH is reported. This catalytic system is effective for various methylation reactions: (1) the β-methylation of primary alcohols, including aryl, aliphatic, and heterocyclic alcohols, (2) the α-methylation

  一种通用，选择性和可循环利用的非均相催化方法，是在无氧化剂的条件下，使用载有Pt的碳（Pt / C）催化剂在NaOH的存在下，用甲醇在醇，酮和吲哚中的C–H键进行甲基化的方法是报告。该催化体系对各种甲基化反应均有效：（1）伯醇（包括芳基，脂肪族和杂环醇）的β-甲基化；（2）酮的α-甲基化；（3）选择性C3-吲哚的甲基化。反应由借氢机制驱动。反应开始于将醇脱氢得到醛，然后将其与亲核试剂（醛，酮或吲哚）进行缩合反应，然后通过Pt–H物种将缩合产物氢化以生成所需的醛。产品。在这项研究中探讨的所有甲基化反应中，Pt / C催化剂的周转率均比以前报道的其他均相催化体系高得多。而且，证明了如在不同金属表面上的密度泛函理论计算所揭示的，Pt的高催化活性可以根据氢在金属表面上的吸附能而合理化。
• PROCESS OF MAKING SOMATOSTATIN MODULATORS
  申请人：Crinetics Pharmaceuticals, Inc.

  公开号：US20190218202A1

  公开（公告）日：2019-07-18

  Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.

  本文描述了一些肽类抑制素调节剂化合物，制备这类化合物的方法，包含这类化合物的药物组合物和药物，以及利用这类化合物治疗需要调节肽类抑制素活性的疾病、症状或疾病的方法。

表征谱图